Avalo Therapeutics, Inc.
AVTX
$4.78
-$0.10-2.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -332.65% | 540.65% | 1,301.79% | -1,118.38% | 16.75% |
| Total Depreciation and Amortization | 58.14% | -17.07% | -19.51% | 3.03% | 22.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -100.00% |
| Total Other Non-Cash Items | 295.13% | -3,943.32% | -12,169.47% | 11,052.16% | -7.16% |
| Change in Net Operating Assets | -820.00% | 58.59% | 68.15% | 17.07% | 144.04% |
| Cash from Operations | -443.89% | -68.62% | -47.68% | 38.30% | 29.80% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 367.67% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6,944,200.00% | -100.00% | -100.00% | 741.03% | -98.78% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,770,800.00% | -100.00% | -178.93% | 690.02% | -98.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,004.70% | -398.70% | -60.67% | 2,784.25% | 28.33% |